Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort

Charlotte Le Cornet; Audrey Y Jung; Theron S Johnson; Sabine Behrens; Nadia Obi; Heiko Becher; Jenny Chang-Claude; Renée T Fortner

doi:10.1186/s13058-023-01625-4

Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort

Standard

Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort. / Le Cornet, Charlotte; Jung, Audrey Y; Johnson, Theron S; Behrens, Sabine; Obi, Nadia; Becher, Heiko; Chang-Claude, Jenny; Fortner, Renée T.

In: BREAST CANCER RES, Vol. 25, No. 1, 17.04.2023, p. 42.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Le Cornet, C, Jung, AY, Johnson, TS, Behrens, S, Obi, N, Becher, H, Chang-Claude, J & Fortner, RT 2023, 'Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort', BREAST CANCER RES, vol. 25, no. 1, pp. 42. https://doi.org/10.1186/s13058-023-01625-4

APA

Le Cornet, C., Jung, A. Y., Johnson, T. S., Behrens, S., Obi, N., Becher, H., Chang-Claude, J., & Fortner, R. T. (2023). Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort. BREAST CANCER RES, 25(1), 42. https://doi.org/10.1186/s13058-023-01625-4

Vancouver

Le Cornet C, Jung AY, Johnson TS, Behrens S, Obi N, Becher H et al. Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort. BREAST CANCER RES. 2023 Apr 17;25(1):42. https://doi.org/10.1186/s13058-023-01625-4

Bibtex

@article{45f8e56f19aa452fa5066f2311534a42,

title = "Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort",

abstract = "BACKGROUND: Experimental studies suggest a role for osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in mammary tumor development and progression. These biomarkers have been minimally investigated with respect to outcomes in breast cancer patients.METHODS: OPG and TRAIL were evaluated in blood samples collected from 2459 breast cancer patients enrolled in the MARIE study, a prospective population-based patient cohort, at median of 129 days after diagnosis. Participants were between ages 50 and 74 at diagnosis and recruited from 2002 to 2005 in two regions of Germany. Follow-up for recurrence and mortality was conducted through June 2015. Delayed-entry Cox proportional hazards regression was used to assess associations between OPG and TRAIL with all-cause and breast cancer-specific mortality, and recurrence, both overall and by tumor hormone receptor status.RESULTS: Median follow-up time was 11.7 years, with 485 deaths reported (277 breast cancer-specific). Higher OPG concentrations were associated with a higher risk of all-cause mortality (hazard ratio for 1-unit log2-transformed concentration (HRlog2) = 1.24 (95% confidence interval 1.03-1.49). Associations were observed in women diagnosed with ER-PR- tumors or discordant hormone receptor status (ER-PR-, HRlog2 = 1.93 (1.20-3.10); discordant ERPR, 1.70 (1.03-2.81)), but not for women with ER + PR + tumors (HRlog2 = 1.06 (0.83-1.35)). OPG was associated with a higher risk of recurrence among women with ER-PR- disease (HRlog2 = 2.18 (1.39-3.40)). We observed no associations between OPG and breast cancer-specific survival, or for TRAIL and any outcome.CONCLUSIONS: Higher circulating OPG may be a biomarker of a higher risk of poor outcome among women diagnosed with ER- breast cancer. Further mechanistic studies are warranted.",

keywords = "Humans, Female, Middle Aged, Aged, Breast Neoplasms/pathology, Osteoprotegerin, Prospective Studies, Ligands, TNF-Related Apoptosis-Inducing Ligand, Tumor Necrosis Factor-alpha, Apoptosis, Biomarkers, Hormones",

author = "{Le Cornet}, Charlotte and Jung, {Audrey Y} and Johnson, {Theron S} and Sabine Behrens and Nadia Obi and Heiko Becher and Jenny Chang-Claude and Fortner, {Ren{\'e}e T}",

note = "{\textcopyright} 2023. The Author(s).",

year = "2023",

month = apr,

day = "17",

doi = "10.1186/s13058-023-01625-4",

language = "English",

volume = "25",

pages = "42",

journal = "BREAST CANCER RES",

issn = "1465-5411",

publisher = "BioMed Central Ltd.",

number = "1",

}

RIS

TY - JOUR

T1 - Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort

AU - Le Cornet, Charlotte

AU - Jung, Audrey Y

AU - Johnson, Theron S

AU - Behrens, Sabine

AU - Obi, Nadia

AU - Becher, Heiko

AU - Chang-Claude, Jenny

AU - Fortner, Renée T

PY - 2023/4/17

Y1 - 2023/4/17

N2 - BACKGROUND: Experimental studies suggest a role for osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in mammary tumor development and progression. These biomarkers have been minimally investigated with respect to outcomes in breast cancer patients.METHODS: OPG and TRAIL were evaluated in blood samples collected from 2459 breast cancer patients enrolled in the MARIE study, a prospective population-based patient cohort, at median of 129 days after diagnosis. Participants were between ages 50 and 74 at diagnosis and recruited from 2002 to 2005 in two regions of Germany. Follow-up for recurrence and mortality was conducted through June 2015. Delayed-entry Cox proportional hazards regression was used to assess associations between OPG and TRAIL with all-cause and breast cancer-specific mortality, and recurrence, both overall and by tumor hormone receptor status.RESULTS: Median follow-up time was 11.7 years, with 485 deaths reported (277 breast cancer-specific). Higher OPG concentrations were associated with a higher risk of all-cause mortality (hazard ratio for 1-unit log2-transformed concentration (HRlog2) = 1.24 (95% confidence interval 1.03-1.49). Associations were observed in women diagnosed with ER-PR- tumors or discordant hormone receptor status (ER-PR-, HRlog2 = 1.93 (1.20-3.10); discordant ERPR, 1.70 (1.03-2.81)), but not for women with ER + PR + tumors (HRlog2 = 1.06 (0.83-1.35)). OPG was associated with a higher risk of recurrence among women with ER-PR- disease (HRlog2 = 2.18 (1.39-3.40)). We observed no associations between OPG and breast cancer-specific survival, or for TRAIL and any outcome.CONCLUSIONS: Higher circulating OPG may be a biomarker of a higher risk of poor outcome among women diagnosed with ER- breast cancer. Further mechanistic studies are warranted.

AB - BACKGROUND: Experimental studies suggest a role for osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in mammary tumor development and progression. These biomarkers have been minimally investigated with respect to outcomes in breast cancer patients.METHODS: OPG and TRAIL were evaluated in blood samples collected from 2459 breast cancer patients enrolled in the MARIE study, a prospective population-based patient cohort, at median of 129 days after diagnosis. Participants were between ages 50 and 74 at diagnosis and recruited from 2002 to 2005 in two regions of Germany. Follow-up for recurrence and mortality was conducted through June 2015. Delayed-entry Cox proportional hazards regression was used to assess associations between OPG and TRAIL with all-cause and breast cancer-specific mortality, and recurrence, both overall and by tumor hormone receptor status.RESULTS: Median follow-up time was 11.7 years, with 485 deaths reported (277 breast cancer-specific). Higher OPG concentrations were associated with a higher risk of all-cause mortality (hazard ratio for 1-unit log2-transformed concentration (HRlog2) = 1.24 (95% confidence interval 1.03-1.49). Associations were observed in women diagnosed with ER-PR- tumors or discordant hormone receptor status (ER-PR-, HRlog2 = 1.93 (1.20-3.10); discordant ERPR, 1.70 (1.03-2.81)), but not for women with ER + PR + tumors (HRlog2 = 1.06 (0.83-1.35)). OPG was associated with a higher risk of recurrence among women with ER-PR- disease (HRlog2 = 2.18 (1.39-3.40)). We observed no associations between OPG and breast cancer-specific survival, or for TRAIL and any outcome.CONCLUSIONS: Higher circulating OPG may be a biomarker of a higher risk of poor outcome among women diagnosed with ER- breast cancer. Further mechanistic studies are warranted.

KW - Humans

KW - Female

KW - Middle Aged

KW - Aged

KW - Breast Neoplasms/pathology

KW - Osteoprotegerin

KW - Prospective Studies

KW - Ligands

KW - TNF-Related Apoptosis-Inducing Ligand

KW - Tumor Necrosis Factor-alpha

KW - Apoptosis

KW - Biomarkers

KW - Hormones

U2 - 10.1186/s13058-023-01625-4

DO - 10.1186/s13058-023-01625-4

M3 - SCORING: Journal article

C2 - 37069615

VL - 25

SP - 42

JO - BREAST CANCER RES

JF - BREAST CANCER RES

SN - 1465-5411

IS - 1

ER -